img

Global Granulomatosis with Polyangiitis Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Granulomatosis with Polyangiitis Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Granulomatosis with Polyangiitis Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Granulomatosis with Polyangiitis Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospital and Clinic are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Granulomatosis with Polyangiitis Drug industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Granulomatosis with Polyangiitis Drug key manufacturers include Bionovis SA, Bristol-Myers Squibb Company, ChemoCentryx Inc, Coherus BioSciences Inc, Genor BioPharma Co Ltd, GlaxoSmithKline Plc, Iltoo Pharma, Panacea Biotec Ltd and Sandoz International GmbH, etc. Bionovis SA, Bristol-Myers Squibb Company, ChemoCentryx Inc are top 3 players and held % sales share in total in 2022.
Granulomatosis with Polyangiitis Drug can be divided into Benralizumab, Avacopan, Rituximab Biosimilar and Others, etc. Benralizumab is the mainstream product in the market, accounting for % sales share globally in 2022.
Granulomatosis with Polyangiitis Drug is widely used in various fields, such as Hospital, Clinic and Others,, etc. Hospital provides greatest supports to the Granulomatosis with Polyangiitis Drug industry development. In 2022, global % sales of Granulomatosis with Polyangiitis Drug went into Hospital filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Granulomatosis with Polyangiitis Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Bionovis SA
Bristol-Myers Squibb Company
ChemoCentryx Inc
Coherus BioSciences Inc
Genor BioPharma Co Ltd
GlaxoSmithKline Plc
Iltoo Pharma
Panacea Biotec Ltd
Sandoz International GmbH
The International Biotechnology Center (IBC) Generium
Segment by Type
Benralizumab
Avacopan
Rituximab Biosimilar
Others

Segment by Application


Hospital
Clinic
Others

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Granulomatosis with Polyangiitis Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Granulomatosis with Polyangiitis Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Granulomatosis with Polyangiitis Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Granulomatosis with Polyangiitis Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Granulomatosis with Polyangiitis Drug introduction, etc. Granulomatosis with Polyangiitis Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Granulomatosis with Polyangiitis Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Granulomatosis with Polyangiitis Drug Market Overview
1.1 Granulomatosis with Polyangiitis Drug Product Overview
1.2 Granulomatosis with Polyangiitis Drug Market Segment by Type
1.2.1 Benralizumab
1.2.2 Avacopan
1.2.3 Rituximab Biosimilar
1.2.4 Others
1.3 Global Granulomatosis with Polyangiitis Drug Market Size by Type
1.3.1 Global Granulomatosis with Polyangiitis Drug Market Size Overview by Type (2018-2034)
1.3.2 Global Granulomatosis with Polyangiitis Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Granulomatosis with Polyangiitis Drug Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Granulomatosis with Polyangiitis Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Granulomatosis with Polyangiitis Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Granulomatosis with Polyangiitis Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Breakdown by Type (2018-2024)
2 Global Granulomatosis with Polyangiitis Drug Market Competition by Company
2.1 Global Top Players by Granulomatosis with Polyangiitis Drug Sales (2018-2024)
2.2 Global Top Players by Granulomatosis with Polyangiitis Drug Revenue (2018-2024)
2.3 Global Top Players by Granulomatosis with Polyangiitis Drug Price (2018-2024)
2.4 Global Top Manufacturers Granulomatosis with Polyangiitis Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Granulomatosis with Polyangiitis Drug Market Competitive Situation and Trends
2.5.1 Granulomatosis with Polyangiitis Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Granulomatosis with Polyangiitis Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Granulomatosis with Polyangiitis Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Granulomatosis with Polyangiitis Drug Market
2.8 Key Manufacturers Granulomatosis with Polyangiitis Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Granulomatosis with Polyangiitis Drug Status and Outlook by Region
3.1 Global Granulomatosis with Polyangiitis Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Granulomatosis with Polyangiitis Drug Historic Market Size by Region
3.2.1 Global Granulomatosis with Polyangiitis Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Granulomatosis with Polyangiitis Drug Sales in Value by Region (2018-2024)
3.2.3 Global Granulomatosis with Polyangiitis Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Granulomatosis with Polyangiitis Drug Forecasted Market Size by Region
3.3.1 Global Granulomatosis with Polyangiitis Drug Sales in Volume by Region (2024-2034)
3.3.2 Global Granulomatosis with Polyangiitis Drug Sales in Value by Region (2024-2034)
3.3.3 Global Granulomatosis with Polyangiitis Drug Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Granulomatosis with Polyangiitis Drug by Application
4.1 Granulomatosis with Polyangiitis Drug Market Segment by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Granulomatosis with Polyangiitis Drug Market Size by Application
4.2.1 Global Granulomatosis with Polyangiitis Drug Market Size Overview by Application (2018-2034)
4.2.2 Global Granulomatosis with Polyangiitis Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Granulomatosis with Polyangiitis Drug Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Granulomatosis with Polyangiitis Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Granulomatosis with Polyangiitis Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Granulomatosis with Polyangiitis Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Breakdown by Application (2018-2024)
5 North America Granulomatosis with Polyangiitis Drug by Country
5.1 North America Granulomatosis with Polyangiitis Drug Historic Market Size by Country
5.1.1 North America Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Granulomatosis with Polyangiitis Drug Sales in Value by Country (2018-2024)
5.2 North America Granulomatosis with Polyangiitis Drug Forecasted Market Size by Country
5.2.1 North America Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2024-2034)
5.2.2 North America Granulomatosis with Polyangiitis Drug Sales in Value by Country (2024-2034)
6 Europe Granulomatosis with Polyangiitis Drug by Country
6.1 Europe Granulomatosis with Polyangiitis Drug Historic Market Size by Country
6.1.1 Europe Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Granulomatosis with Polyangiitis Drug Sales in Value by Country (2018-2024)
6.2 Europe Granulomatosis with Polyangiitis Drug Forecasted Market Size by Country
6.2.1 Europe Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2024-2034)
6.2.2 Europe Granulomatosis with Polyangiitis Drug Sales in Value by Country (2024-2034)
7 Asia-Pacific Granulomatosis with Polyangiitis Drug by Region
7.1 Asia-Pacific Granulomatosis with Polyangiitis Drug Historic Market Size by Region
7.1.1 Asia-Pacific Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Granulomatosis with Polyangiitis Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Granulomatosis with Polyangiitis Drug Sales in Value by Region (2024-2034)
8 Latin America Granulomatosis with Polyangiitis Drug by Country
8.1 Latin America Granulomatosis with Polyangiitis Drug Historic Market Size by Country
8.1.1 Latin America Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Granulomatosis with Polyangiitis Drug Sales in Value by Country (2018-2024)
8.2 Latin America Granulomatosis with Polyangiitis Drug Forecasted Market Size by Country
8.2.1 Latin America Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2024-2034)
8.2.2 Latin America Granulomatosis with Polyangiitis Drug Sales in Value by Country (2024-2034)
9 Middle East and Africa Granulomatosis with Polyangiitis Drug by Country
9.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Historic Market Size by Country
9.1.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Granulomatosis with Polyangiitis Drug Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Bionovis SA
10.1.1 Bionovis SA Company Information
10.1.2 Bionovis SA Introduction and Business Overview
10.1.3 Bionovis SA Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Bionovis SA Granulomatosis with Polyangiitis Drug Products Offered
10.1.5 Bionovis SA Recent Development
10.2 Bristol-Myers Squibb Company
10.2.1 Bristol-Myers Squibb Company Company Information
10.2.2 Bristol-Myers Squibb Company Introduction and Business Overview
10.2.3 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Products Offered
10.2.5 Bristol-Myers Squibb Company Recent Development
10.3 ChemoCentryx Inc
10.3.1 ChemoCentryx Inc Company Information
10.3.2 ChemoCentryx Inc Introduction and Business Overview
10.3.3 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Products Offered
10.3.5 ChemoCentryx Inc Recent Development
10.4 Coherus BioSciences Inc
10.4.1 Coherus BioSciences Inc Company Information
10.4.2 Coherus BioSciences Inc Introduction and Business Overview
10.4.3 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Products Offered
10.4.5 Coherus BioSciences Inc Recent Development
10.5 Genor BioPharma Co Ltd
10.5.1 Genor BioPharma Co Ltd Company Information
10.5.2 Genor BioPharma Co Ltd Introduction and Business Overview
10.5.3 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Products Offered
10.5.5 Genor BioPharma Co Ltd Recent Development
10.6 GlaxoSmithKline Plc
10.6.1 GlaxoSmithKline Plc Company Information
10.6.2 GlaxoSmithKline Plc Introduction and Business Overview
10.6.3 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
10.6.4 GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Products Offered
10.6.5 GlaxoSmithKline Plc Recent Development
10.7 Iltoo Pharma
10.7.1 Iltoo Pharma Company Information
10.7.2 Iltoo Pharma Introduction and Business Overview
10.7.3 Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Iltoo Pharma Granulomatosis with Polyangiitis Drug Products Offered
10.7.5 Iltoo Pharma Recent Development
10.8 Panacea Biotec Ltd
10.8.1 Panacea Biotec Ltd Company Information
10.8.2 Panacea Biotec Ltd Introduction and Business Overview
10.8.3 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Products Offered
10.8.5 Panacea Biotec Ltd Recent Development
10.9 Sandoz International GmbH
10.9.1 Sandoz International GmbH Company Information
10.9.2 Sandoz International GmbH Introduction and Business Overview
10.9.3 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Sandoz International GmbH Granulomatosis with Polyangiitis Drug Products Offered
10.9.5 Sandoz International GmbH Recent Development
10.10 The International Biotechnology Center (IBC) Generium
10.10.1 The International Biotechnology Center (IBC) Generium Company Information
10.10.2 The International Biotechnology Center (IBC) Generium Introduction and Business Overview
10.10.3 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales, Revenue and Gross Margin (2018-2024)
10.10.4 The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Products Offered
10.10.5 The International Biotechnology Center (IBC) Generium Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Granulomatosis with Polyangiitis Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Granulomatosis with Polyangiitis Drug Industrial Chain Analysis
11.4 Granulomatosis with Polyangiitis Drug Market Dynamics
11.4.1 Granulomatosis with Polyangiitis Drug Industry Trends
11.4.2 Granulomatosis with Polyangiitis Drug Market Drivers
11.4.3 Granulomatosis with Polyangiitis Drug Market Challenges
11.4.4 Granulomatosis with Polyangiitis Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Granulomatosis with Polyangiitis Drug Distributors
12.3 Granulomatosis with Polyangiitis Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Benralizumab
Table 2. Major Company of Avacopan
Table 3. Major Company of Rituximab Biosimilar
Table 4. Major Company of Others
Table 5. Global Granulomatosis with Polyangiitis Drug Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Granulomatosis with Polyangiitis Drug Sales by Type (2018-2024) & (K Pcs)
Table 7. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type (2018-2024)
Table 8. Global Granulomatosis with Polyangiitis Drug Sales by Type (2018-2024) & (US& Million)
Table 9. Global Granulomatosis with Polyangiitis Drug Market Share in Value by Type (2018-2024)
Table 10. Global Granulomatosis with Polyangiitis Drug Price by Type (2018-2024) & (USD/Pcs)
Table 11. Global Granulomatosis with Polyangiitis Drug Sales by Type (2024-2034) & (K Pcs)
Table 12. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type (2024-2034)
Table 13. Global Granulomatosis with Polyangiitis Drug Sales by Type (2024-2034) & (US$ Million)
Table 14. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type (2024-2034)
Table 15. Global Granulomatosis with Polyangiitis Drug Price by Type (2024-2034) & (USD/Pcs)
Table 16. North America Granulomatosis with Polyangiitis Drug Sales by Type (2018-2024) & (K Pcs)
Table 17. North America Granulomatosis with Polyangiitis Drug Sales by Type (2018-2024) & (US$ Million)
Table 18. Europe Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2018-2024)
Table 19. Europe Granulomatosis with Polyangiitis Drug Sales by Type (2018-2024) & (US$ Million)
Table 20. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2018-2024)
Table 21. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Type (2018-2024) & (US$ Million)
Table 22. Latin America Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2018-2024)
Table 23. Latin America Granulomatosis with Polyangiitis Drug Sales by Type (2018-2024) & (US$ Million)
Table 24. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales (K Pcs) by Type (2018-2024)
Table 25. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Type (2018-2024) & (US$ Million)
Table 26. Global Granulomatosis with Polyangiitis Drug Sales by Company (2018-2024) & (K Pcs)
Table 27. Global Granulomatosis with Polyangiitis Drug Sales Share by Company (2018-2024)
Table 28. Global Granulomatosis with Polyangiitis Drug Revenue by Company (2018-2024) & (US$ Million)
Table 29. Global Granulomatosis with Polyangiitis Drug Revenue Share by Company (2018-2024)
Table 30. Global Market Granulomatosis with Polyangiitis Drug Price by Company (2018-2024) & (USD/Pcs)
Table 31. Global Granulomatosis with Polyangiitis Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 32. Global Granulomatosis with Polyangiitis Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Granulomatosis with Polyangiitis Drug as of 2022)
Table 34. Date of Key Manufacturers Enter into Granulomatosis with Polyangiitis Drug Market
Table 35. Key Manufacturers Granulomatosis with Polyangiitis Drug Product Type
Table 36. Mergers & Acquisitions, Expansion Plans
Table 37. Global Granulomatosis with Polyangiitis Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 38. Global Granulomatosis with Polyangiitis Drug Sales by Region (2018-2024) & (K Pcs)
Table 39. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Region (2018-2024)
Table 40. Global Granulomatosis with Polyangiitis Drug Sales by Region (2018-2024) & (US$ Million)
Table 41. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Region (2018-2024)
Table 42. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 43. Global Granulomatosis with Polyangiitis Drug Sales by Region (2024-2034) & (K Pcs)
Table 44. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Region (2024-2034)
Table 45. Global Granulomatosis with Polyangiitis Drug Sales by Region (2024-2034) & (US$ Million)
Table 46. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Region (2024-2034)
Table 47. Global Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 48. Global Granulomatosis with Polyangiitis Drug Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 49. Global Granulomatosis with Polyangiitis Drug Sales by Application (2018-2024) & (K Pcs)
Table 50. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application (2018-2024)
Table 51. Global Granulomatosis with Polyangiitis Drug Sales by Application (2018-2024) & (US$ Million)
Table 52. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application (2018-2024)
Table 53. Global Granulomatosis with Polyangiitis Drug Price by Application (2018-2024) & (USD/Pcs)
Table 54. Global Granulomatosis with Polyangiitis Drug Sales by Application (2024-2034) & (K Pcs)
Table 55. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application (2024-2034)
Table 56. Global Granulomatosis with Polyangiitis Drug Sales by Application (2024-2034) & (US$ Million)
Table 57. Global Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application (2024-2034)
Table 58. Global Granulomatosis with Polyangiitis Drug Price by Application (2024-2034) & (USD/Pcs)
Table 59. North America Granulomatosis with Polyangiitis Drug Sales by Application (2018-2024) (K Pcs)
Table 60. North America Granulomatosis with Polyangiitis Drug Sales by Application (2018-2024) & (US$ Million)
Table 61. Europe Granulomatosis with Polyangiitis Drug Sales by Application (2018-2024) (K Pcs)
Table 62. Europe Granulomatosis with Polyangiitis Drug Sales by Application (2018-2024) & (US$ Million)
Table 63. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Application (2018-2024) (K Pcs)
Table 64. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Application (2018-2024) & (US$ Million)
Table 65. Latin America Granulomatosis with Polyangiitis Drug Sales by Application (2018-2024) (K Pcs)
Table 66. Latin America Granulomatosis with Polyangiitis Drug Sales by Application (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Application (2018-2024) (K Pcs)
Table 68. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Application (2018-2024) & (US$ Million)
Table 69. North America Granulomatosis with Polyangiitis Drug Sales by Country (2018-2024) & (K Pcs)
Table 70. North America Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Country (2018-2024)
Table 71. North America Granulomatosis with Polyangiitis Drug Sales by Country (2018-2024) & (US$ Million)
Table 72. North America Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Country (2018-2024)
Table 73. North America Granulomatosis with Polyangiitis Drug Sales by Country (2024-2034) & (K Pcs)
Table 74. North America Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Country (2024-2034)
Table 75. North America Granulomatosis with Polyangiitis Drug Sales by Country (2024-2034) & (US$ Million)
Table 76. North America Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Country (2024-2034)
Table 77. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2018-2024) & (K Pcs)
Table 78. Europe Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Country (2018-2024)
Table 79. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2018-2024) & (US$ Million)
Table 80. Europe Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Country (2018-2024)
Table 81. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2024-2034) & (K Pcs)
Table 82. Europe Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Country (2024-2034)
Table 83. Europe Granulomatosis with Polyangiitis Drug Sales by Country (2024-2034) & (US$ Million)
Table 84. Europe Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Country (2024-2034)
Table 85. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Region (2018-2024) & (K Pcs)
Table 86. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Region (2018-2024)
Table 87. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Region (2018-2024) & (US$ Million)
Table 88. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Region (2018-2024)
Table 89. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Region (2024-2034) & (K Pcs)
Table 90. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Region (2024-2034)
Table 91. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales by Region (2024-2034) & (US$ Million)
Table 92. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Region (2024-2034)
Table 93. Latin America Granulomatosis with Polyangiitis Drug Sales by Country (2018-2024) & (K Pcs)
Table 94. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Country (2018-2024)
Table 95. Latin America Granulomatosis with Polyangiitis Drug Sales by Country (2018-2024) & (US$ Million)
Table 96. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Country (2018-2024)
Table 97. Latin America Granulomatosis with Polyangiitis Drug Sales by Country (2024-2034) & (K Pcs)
Table 98. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Country (2024-2034)
Table 99. Latin America Granulomatosis with Polyangiitis Drug Sales by Country (2024-2034) & (US$ Million)
Table 100. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Country (2024-2034)
Table 101. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2018-2024) & (K Pcs)
Table 102. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Country (2018-2024)
Table 103. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2018-2024) & (US$ Million)
Table 104. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Country (2018-2024)
Table 105. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2024-2034) & (K Pcs)
Table 106. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Country (2024-2034)
Table 107. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales by Country (2024-2034) & (US$ Million)
Table 108. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Country (2024-2034)
Table 109. Bionovis SA Company Information
Table 110. Bionovis SA Introduction and Business Overview
Table 111. Bionovis SA Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 112. Bionovis SA Granulomatosis with Polyangiitis Drug Product
Table 113. Bionovis SA Recent Development
Table 114. Bristol-Myers Squibb Company Company Information
Table 115. Bristol-Myers Squibb Company Introduction and Business Overview
Table 116. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 117. Bristol-Myers Squibb Company Granulomatosis with Polyangiitis Drug Product
Table 118. Bristol-Myers Squibb Company Recent Development
Table 119. ChemoCentryx Inc Company Information
Table 120. ChemoCentryx Inc Introduction and Business Overview
Table 121. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 122. ChemoCentryx Inc Granulomatosis with Polyangiitis Drug Product
Table 123. ChemoCentryx Inc Recent Development
Table 124. Coherus BioSciences Inc Company Information
Table 125. Coherus BioSciences Inc Introduction and Business Overview
Table 126. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 127. Coherus BioSciences Inc Granulomatosis with Polyangiitis Drug Product
Table 128. Coherus BioSciences Inc Recent Development
Table 129. Genor BioPharma Co Ltd Company Information
Table 130. Genor BioPharma Co Ltd Introduction and Business Overview
Table 131. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 132. Genor BioPharma Co Ltd Granulomatosis with Polyangiitis Drug Product
Table 133. Genor BioPharma Co Ltd Recent Development
Table 134. GlaxoSmithKline Plc Company Information
Table 135. GlaxoSmithKline Plc Introduction and Business Overview
Table 136. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 137. GlaxoSmithKline Plc Granulomatosis with Polyangiitis Drug Product
Table 138. GlaxoSmithKline Plc Recent Development
Table 139. Iltoo Pharma Company Information
Table 140. Iltoo Pharma Introduction and Business Overview
Table 141. Iltoo Pharma Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 142. Iltoo Pharma Granulomatosis with Polyangiitis Drug Product
Table 143. Iltoo Pharma Recent Development
Table 144. Panacea Biotec Ltd Company Information
Table 145. Panacea Biotec Ltd Introduction and Business Overview
Table 146. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 147. Panacea Biotec Ltd Granulomatosis with Polyangiitis Drug Product
Table 148. Panacea Biotec Ltd Recent Development
Table 149. Sandoz International GmbH Company Information
Table 150. Sandoz International GmbH Introduction and Business Overview
Table 151. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 152. Sandoz International GmbH Granulomatosis with Polyangiitis Drug Product
Table 153. Sandoz International GmbH Recent Development
Table 154. The International Biotechnology Center (IBC) Generium Company Information
Table 155. The International Biotechnology Center (IBC) Generium Introduction and Business Overview
Table 156. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 157. The International Biotechnology Center (IBC) Generium Granulomatosis with Polyangiitis Drug Product
Table 158. The International Biotechnology Center (IBC) Generium Recent Development
Table 159. Key Raw Materials Lists
Table 160. Raw Materials Key Suppliers Lists
Table 161. Granulomatosis with Polyangiitis Drug Market Trends
Table 162. Granulomatosis with Polyangiitis Drug Market Drivers
Table 163. Granulomatosis with Polyangiitis Drug Market Challenges
Table 164. Granulomatosis with Polyangiitis Drug Market Restraints
Table 165. Granulomatosis with Polyangiitis Drug Distributors List
Table 166. Granulomatosis with Polyangiitis Drug Downstream Customers
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
List of Figures
Figure 1. Granulomatosis with Polyangiitis Drug Product Picture
Figure 2. Global Granulomatosis with Polyangiitis Drug Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Granulomatosis with Polyangiitis Drug Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Granulomatosis with Polyangiitis Drug Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of Benralizumab
Figure 6. Global Benralizumab Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of Avacopan
Figure 8. Global Avacopan Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of Rituximab Biosimilar
Figure 10. Global Rituximab Biosimilar Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of Others
Figure 12. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Global Granulomatosis with Polyangiitis Drug Sales by Type (2018-2034) & (US$ Million)
Figure 14. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Type in 2022 & 2034
Figure 15. North America Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type in 2022
Figure 16. North America Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type in 2022
Figure 17. Europe Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type in 2022
Figure 18. Europe Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type in 2022
Figure 19. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type in 2022
Figure 20. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type in 2022
Figure 21. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type in 2022
Figure 22. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type in 2022
Figure 23. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Type in 2022
Figure 24. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Type in 2022
Figure 25. The 5 and 10 Largest Manufacturers in the World: Market Share by Granulomatosis with Polyangiitis Drug Sales in 2022
Figure 26. The 5 and 10 Largest Manufacturers in the World: Market Share by Granulomatosis with Polyangiitis Drug Revenue in 2022
Figure 27. Granulomatosis with Polyangiitis Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 28. Product Picture of Hospital
Figure 29. Global Hospital Sales YoY Growth (2018-2034) & (K Pcs)
Figure 30. Product Picture of Clinic
Figure 31. Global Clinic Sales YoY Growth (2018-2034) & (K Pcs)
Figure 32. Product Picture of Others
Figure 33. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 34. Global Granulomatosis with Polyangiitis Drug Sales by Application (2018-2034) & (US$ Million)
Figure 35. Global Granulomatosis with Polyangiitis Drug Sales Market Share by Application in 2022 & 2034
Figure 36. North America Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application in 2022
Figure 37. North America Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application in 2022
Figure 38. Europe Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application in 2022
Figure 39. Europe Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application in 2022
Figure 40. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application in 2022
Figure 41. Asia-Pacific Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application in 2022
Figure 42. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share in Volume by Application in 2022
Figure 43. Latin America Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application in 2022
Figure 44. Middle East and Africa Granulomatosis with Polyangiitis Drug Sales Market Share in Value by Application in 2022
Figure 45. Key Raw Materials Price
Figure 46. Granulomatosis with Polyangiitis Drug Manufacturing Cost Structure
Figure 47. Granulomatosis with Polyangiitis Drug Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries